The recent withdrawal of the calcium antagonist mibefradil
|
|
- Osborn Conley
- 5 years ago
- Views:
Transcription
1 Cardiovascular Drugs Molecular Basis of Cardiovascular Drug Metabolism Implications for Predicting Clinically Important Drug Interactions Darrell R. Abernethy, MD, PhD; David A. Flockhart, MD, PhD The recent withdrawal of the calcium antagonist mibefradil from the market in the United States has refocused attention on drug interactions that involve cardiovascular drugs. 1 It is appropriate to ask whether pharmacokinetic drug interactions like this that pose substantial clinical risk can be predicted and/or prevented. We believe that if the appropriate information is obtained during drug development and effectively communicated to physicians, many episodes such as that involving mibefradil will be predicted and prevented. Many known pharmacokinetic drug interactions with the potential for either excessive drug exposure, effect, and toxicity or decreased drug exposure and loss of drug effect are associated with phase I drug biotransformations. 2 In addition, the importance of P-glycoprotein mediated drug transport is currently being appreciated. 3 Cytochrome P-450 Associated Interactions Major improvements in the scientific tools available to study cytochrome P-450 (CYP) mediated biotransformations over the past decade 4 now permit prediction of potential drug interactions during drug development. In some cases, these tools can be used to determine which of a series of drug candidates should undergo clinical development. They can also be used to understand and identify interactions between drugs that are in clinical use. An important component of this understanding is the challenge to determine the patient risk associated with each potential drug interaction because many pharmacokinetic drug interactions have no meaningful clinical consequence. 5 The CYP family of enzymes, located in the liver and gastrointestinal tract, is the major source of catalytic activity for drug oxidation in humans. 6 This enzyme family consists of 30 isoforms, but only a few have importance in human drug metabolism. This immensely simplifies the understanding of the system for prescribers. Briefly, naming of the CYP enzymes includes designation of the family, subfamily, and gene so that CYP 1(family), A(subfamily), 2(gene) designates the CYP isoform most associated with theophylline biotransformation. 6 Therefore, drugs that inhibit CYP1A2 (eg, ciprofloxacin) are predicted to elevate plasma theophylline and produce toxicity, 7 and exposures that induce CYP1A2 (eg, cigarette smoking) are predicted to reduce theophylline plasma concentrations. 8 The possibility of CYPbased interactions can now be predicted from in vitro data obtained from human liver microsomes or recombinant preparations of pure CYP enzymes. 4 However, in vitro studies can document only that an interaction between a drug or drugs and a CYP enzyme is possible; they cannot predict in vivo distribution or concentration of drug at its site of biotransformation at clinically used doses. Therefore, important predictions should always be tested for validity by confirmatory clinical studies. Predictions of inductive interactions are more difficult with in vitro methods; however, study of CYP enzyme induction in cultured human hepatocytes is an area of rapid progress. 9 These in vitro studies must be done with human enzyme sources as enzymes expressed because enzyme substrate specificity obtained from any animal model do not extrapolate well to humans. 10 The CYP isoforms known to be important for cardiovascular drug biotransformation include CYP3A, CYP2D6, CYP1A2, CYP2C19, and CYP2C9. 4 Table 1 shows selected inhibitory and inductive drug interactions. A more complete listing of drugs that are substrates, inducers, and inhibitors of the CYP isoforms can be found on the web at dml.georgetown.edu/depts/pharmacology/davetab.html. CYP3A and CYP1A2 have highly variable expression across the population, even in the absence of concurrent ingestion of an inhibiting or inducing drug. The population distribution of these enzymatic activities (and therefore clearance of drugs that are metabolized by these enzymes) is continuous, with most individuals having an intermediate level of activity and some individuals having very low or very high activity. In contrast, CYP2C19, CYP2C9, and CYP2D6 activities are significantly influenced by genetic polymorphisms that occur with frequencies that vary among different ethnic groups (Table 2) The clinical consequence of such polymorphisms can be profound. For example, individuals with genetically determined defects in CYP2C9 activity have been reported to require 0.5 mg/d warfarin for adequate anticoagulation 14 because metabolic inactivation of S-warfarin, the active enantiomer, is almost exclusively mediated by CYP2C9. 14,15 Another example is propafenone. In addition to the antiarrhythmic properties of both propafenone and its major metabolite and 5-hydroxypropafenone, propafenone has weak -adrenoceptor blocking activity. Because formation of 5-hydroxypropafenone is via CYP2D6, patients who have genetically deficient From the Division of Clinical Pharmacology, Georgetown University Medical Center, Washington, DC. Correspondence to Darrell R. Abernethy, MD, PhD, Laboratory for Clinical Investigation, National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Dr, Baltimore, MD abernethyd@grc.nia.nih.gov (Circulation. 2000;101: ) 2000 American Heart Association, Inc. Circulation is available at
2 1750 Circulation April 11, 2000 TABLE 1. Some Clinically Important Cardiovascular Drug Interactions Inhibitory interactions (substrate/inhibitor) Inducing interactions (substrate/inducer) Theophylline/ ciprofloxacin Specific CYP Enzyme 1A2 2C19 2C9 3A Theophylline/ cigarette smoking Phenytoin/ omeprazole Warfarin/amiodarone HMG-CoA reductase inhibitors (except pravistatin)/ erythromycin, clarithromycin Phenytoin/ticlopidine Warfarin/fluconazole Cyclosporine, tacrolimus/ verapamil, diltiazem Cisapride/ketoconazole, itraconazole Phenytoin/rifampin Warfarin/ barbiturates A comprehensive listing can be found at Cyclosporine, tacrolimus/ rifampin CYP2D6 activity exhibit markedly greater -adrenoceptor blockade and central nervous system side effects than patients with high CYP2D6 activity. 16,17 Of note, the contribution of CYP2D6 to drug elimination may be obscured if renal clearance is a significant component of elimination kinetics. This is the case with flecainide, for which the documented contribution of the genetic polymorphism in CYP2D has no pharmacodynamic relevance. Renal clearance of unchanged flecainide is a major pathway in individuals with normal renal function. Therefore, only in patients with markedly decreased renal function in whom flecainide biotransformation by CYP2D6 is a major route of clearance would the absence of CYP2D6 activity be associated with further impairment of elimination compared with individuals with wild-type CYP2D6 activity. 21 The biotransformation of most drugs is not carried out by one specific CYP enzyme. Phenytoin biotransformation is catalyzed by both CYP2C19 and CYP2C9. 22,23 Individuals with polymorphically decreased activity of either enzyme have higher serum phenytoin concentration at a given dose. 24,25 The clinical impact of each individual enzyme is diluted, however, because the other enzyme contributes significantly to phenytoin biotransformation. 26 The coincident presence of both 2C9 and 2C19 low-activity variants is extremely rare and has not been evaluated in clinical study. The specificity and potency of the interaction of a drug with a particular CYP enzyme is also central to the definition of the clinical importance of potential inhibitory drug interactions. For example, the potent and specific CYP3A inhibitor itraconazole blocks the biotransformation of 2 drugs, astemizole and simvastatin, each of which is a very specific substrate for CYP3A. When itraconazole is coadministered with either of these drugs, the clinical result may be astemizole-induced torsade de pointes arrhythmia or simvastatin-induced rhabdomyolysis, respectively. 27,28 In contrast, cimetidine, a less potent and less specific CYP3A inhibitor, is associated with neither of these potentially life-threatening drug interactions. P-Glycoprotein Drug Transport and Drug Interactions The role of P-glycoprotein as a drug transporter across cell membranes in cancer chemotherapy is well known, 29 and its role in multiple drug resistance to anticancer drugs has been extensively characterized. 30 Much more recently, with the development of the mdr-1 knockout transgenic mouse, it has become apparent that P-glycoprotein drug transport is much more general, with evidence that it serves as a renal drug transporter, 31 as an efflux pump from the central nervous system for selected drugs, 32 and in the intestinal wall as a barrier to drug absorption. 33 In cardiovascular therapeutics, therapeutic doses of verapamil inhibit P-glycoprotein, and this, in addition to its inhibitory effect on CYP3A, contributes to a marked increase in cyclosporine absorption and availability when the drugs are coadministered. Both inhibition of intestinal CYP3A, limiting cyclosporine metabolism, and P-glycoprotein inhibition, limiting this barrier to absorption, are thought to contribute to this drug interaction. Conversely, cyclosporine, as a P-glycoprotein substrate, competitively inhibits verapamil-mediated P-glycoprotein inhibition. 34 Examples of drugs currently identified as substrates or inhibitors of P-glycoprotein are shown in Table 3. It is important to note that a variety of methods, such as the mdr-1 knockout mouse and other in vitro and in vivo techniques, were used to determine the effect of the listed drug on P-glycoprotein; therefore, in many cases, clinical studies will be needed to establish whether there is a clinical correlate to the laboratory finding. In some cases, clinical studies have already demonstrated an interaction and preclinical work has defined P-glycoprotein as the likely site of the interaction. For example, Fromm et al 35 have been able to establish the mechanism for TABLE 2. Ethnic Variation in CYP Polymorphic Drug Metabolism CYP2D6, % CYP2C19, % CYP2C9, % Absent Present Ultrarapid Absent Present Absent Present African/African-American 8 92? Asian White
3 Abernethy and Flockhart Molecular Basis of CV Drug Metabolism 1751 TABLE 3. Drugs That May Interact With P-Glycoprotein at Therapeutic Doses Cardiovascular Anticancer Other Antiarrhythmics Phenothiazines Amiodarone 34 Vinblastine 46 Chlorpromazine 34 Quinidine 34 Vincristine 46 Fluphenazine 34 Propafenone 34 Doxorubicin 46 Promethazine 34 Calcium antagonists Daunorubicin 46 Trifluoperazine 34 Verapamil 43 Epirubicin 46 Trifluopromazine 34 Diltiazem 44 Idarubicin 46 Paclitaxel 46 Digoxin 35 Docetaxel 46 Pimozide 34 Dipyridamole 34 Etoposide 46 Terfenadine 47 Reserpine 45 Teniposide 46 Ivermectin 48 Spironolactone 34 Mitoxantrone 46 Ketoconazole 36 Dactinomycin 46 Itraconazole 31 Amsacrine 46 Mefloquine 49 Trimetrexate 46 Erythromycin 50 Topotecan 46 Clarithromycin 37 Mithramycin 46 Levofloxacin 31 Mitomycin c 46 Tamoxifen 46 HIV protease inhibitors Indinavir 33 Nelfinavir 33 Saquinavir 33 Immunosuppressives Cyclosporine 51 Tacrolimus 52 Domperidone 53 Loperamide 53 Ondansetron 53 the digoxin-quinidine clinical interaction as that of quinidinemediated inhibition of P-glycoprotein mediated digoxin transport. This clinical interaction, with decreases in both digoxin volume of distribution and digoxin clearance with quinidine coadministration, had previously been without a satisfactory mechanistic explanation. Similarly, the marked increase in digoxin bioavailability with macrolide antibiotic (eg, erythromycin) coadministration had previously been attributed to macrolide-induced change in gut flora. Although antibiotics may impair gut digoxin metabolism, an alternative explanation now appears to be that the macrolide antibiotic additionally inhibits both intestinal P-glycoprotein mediated inhibition of digoxin absorption and renal elimination. 36,37 A series of well-designed clinical studies is required to establish the clinical importance of this new type of drug interaction for the drugs listed in Table 3. Discussion How does this information allow better prediction of potential pharmacokinetic drug interactions with cardiovascular drugs? In vitro study of the metabolism of a drug candidate or a new drug using tissue from human liver preparations and recombinant enzymes allows qualitative definition of the CYP isoforms involved in the biotransformation of the drug of interest. Similarly, in vitro cell systems that express P-glycoprotein can be used to screen for potential interactions. These same experimental systems allow evaluation of the inhibitory potential of other concurrently administered drugs. CYP enzyme inhibition may block biotransformation of the active drug to inactive metabolites, or as in the case of a drug such as losartan, it may block biotransformation of a less active precursor drug to the pharmacologically active metabolite. 38 P-glycoprotein inhibition may alter the gastrointestinal absorption, renal clearance, or access to the central nervous system of concurrently administered P-glycoprotein substrates. In the case of the mibefradil, in vitro and in vivo studies demonstrated that it inhibited both CYP3A and CYP2D6. There was no information about potential P-glycoprotein inhibition. Therefore, the potential for a toxic metabolic drug interaction with HMG CoA reductase inhibitors and nonsedating antihistamines such as astemizole should have been predicted and evaluated in a small, focused, and controlled clinical study. Without knowledge of the possibility of P-glycoprotein effects, no predictions could be made; however, a pharmacokinetic drug interaction with cyclosporine was reported, which raises the possibility of mibefradil effects on P-glycoprotein as well. 39 Instead, only after the list of potentially toxic interactions with coadministered drugs was assembled by the FDA was the drug withdrawn. 1,40,41 In the case of inductive drug interactions, in vitro evaluations are not as fully developed. Human hepatocyte cultures able to maintain the capacity for CYP enzyme induction are in development and may be useful in the future for predictive purposes. 9 Currently, a focused clinical study remains the most useful tool to define a potential interaction involving CYP enzyme induction. The methods described here for the study of CYP enzyme effects are in routine use during development of cardiovascular drugs by pharmaceutical companies. Assessment of the effect of P-glycoprotein (and other drug transport molecules that are only now being defined) is more preliminary, but we predict that such evaluation will soon be routine during drug development. If our collective experience with mibefradil is representative, we are not yet taking full advantage of these methods in drug development. For clinical practice, the increasing availability of simple tables, such as Table 1, allows prediction of potential drug interactions when a drug is concurrently administered with an inhibitor or inducer of its CYP enzyme(s) of biotransformation. Similarly, the potential for P-glycoprotein mediated interactions can be inferred from Table 3. Of note, drug interactions are not always harmful, as in the case of inhibitory interactions between verapamil or diltiazem and cyclosporine that permit a lower dose of cyclosporine to be administered with equal therapeutic benefit but at lower cost. 42 In summary, understanding and predicting potential drug interactions is now far from a purely empiric exercise. Currently, potential pharmacokinetic interactions of known cardiovascular drugs are often predictable, and as new drugs become available, the information needed for prediction
4 1752 Circulation April 11, 2000 should be part of the development program. This information can now be presented in an organized summary that provides prescribers with a simple and rapid means of checking for potential interactions. Acknowledgments This work was supported in part by NIH grants AG-08226, GM , and GM We are grateful to Anne Nguyen and Julita Nieve for assistance in manuscript preparation. References 1. SoRelle R. Withdrawal of Posicor from market. Circulation. 1998;98: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman GA, eds. The Pharmacological Basis of Therapeutics. New York, NY: McGraw Hill; Borst P, Schinkel AH, Smit JJM, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EWHM, Baas F, Zaman GJR. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmacol Ther. 1993;60: Linn JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49: Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI. Clinical importance of interaction of diazepam and cimetidine. N Engl J Med. 1984;310: Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther. 1990;45: Batty KT, Davis TME, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 1995;39: Matsunga SK, Plezia PM, Karol MD, Katz MD, Camilli AE, Benowitz NL. Effects of passive smoking on theophylline clearance. Clin Pharmacol Ther. 1989;46: Li AP, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol. 1997;13: Newton DJ, Wang RW, Lu AYH. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 1995;23: Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. S-mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984;36: Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4: Eichelbaum M, Spannbrucker N, Steinke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979;16: Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9. Pharmacogenetics. 1997;7: Kunze KL, Wienkers LC, Thummel KE, Trager WF. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996;24: Siddoway LA, Thompson KA, McAllister BC, Wang T, Wilkinson GR, Roden DM, Woosley RL. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987;75: Funk-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med. 1990;322: Birgersdotter UM, Wong W, Turgeon J, Roden DM. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol. 1992;33: Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M, Jaillon P. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther. 1994;55: Munafo A, Buclin T, Tuto D, Biollaz J. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur J Clin Pharmacol. 1992;43: Evers J, Eichelbaum M, Kroemer HK. Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death. Ther Drug Monit. 1994;16: Bajpai M, Roskos LK, Shen DD, Trager WF, Levy RH. Role of S-mephenytoin hydroxylase in the metabolism of phenytoin. Pharmacol Res. 1994;11(suppl 1):348. Abstract. 23. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cdnaexpressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 1991;175: Odani A, Hashimoto Y, Otsuki Y, Umai Y, Hatori H, Furushok K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62: Bajpai M, Roskos LK, Shen DD, Levy R. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24: Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39: Legebrve RA, Van Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effect of astemizole. Br J Clin Pharmacol. 1997;43: Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63: Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev. 1997;77: Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62: Ito T, Yano I, Tanaka K, Inui K-I. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK 1. J Pharmacol Exp Ther. 1997;282: Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, Sawada Y. P-glycoproteinmediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998;42: Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101: Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: development of a [ 3 H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999;288: Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99: Salphati L, Benet LZ. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology. 1998;56: Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K-I. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64: Williamson KM, Patterson H, McQueen RH, Adams KF, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63: Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am J Cardiol. 1997;80(suppl 4B):4C 11C. 40. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 1998;351: Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA. 1998;280: Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporine pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol. 1997;44: Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta. 1997;1361:
5 Abernethy and Flockhart Molecular Basis of CV Drug Metabolism Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta. 1997;1361: Jette L, Murphy GF, Leclerc J-M, Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol. 1995;50: Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40(suppl):S13 S Hait WN, Gesmonde JF, Murren JR, Yang J-M, Chen H-X, Reiss M. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993;45: Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77: Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, Tilley L. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol. 1996;52: Hofsli E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer. 1989;44: Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96: Saeke T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268: Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97: KEY WORDS: drugs metabolism molecular biology
Cytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationCytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences
Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration
More informationWho remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?
Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationVERAPAMIL METABOLITE EXPOSURE IN OLDER AND YOUNGER MEN DURING STEADY-STATE ORAL VERAPAMIL ADMINISTRATION
0090-9556/00/2807-0760 765 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 7 U.S. Government work not protected by U.S. copyright Printed in U.S.A. DMD 28:760 765, 2000 /1847/835198 VERAPAMIL METABOLITE EXPOSURE
More informationFarmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano
Farmacologia di genere Prof. Alberto Corsini Università degli Studi di Milano Women have been less enrolled in clinical trials A gender-specific analysis usually is not included in the evaluation of results
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationDrug Interactions, from bench to bedside
Drug Interactions, from bench to bedside Candidate to Market, The Paterson Institute for Cancer Research, Manchester, UK Michael Griffin PhD Overview of presentation To understand the importance of drug-drug
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationThe Case of Libby Zion and Dangerous Drug Interactions
The Case of Libby Zion and Dangerous Drug Interactions J.R.White, PA, PharmD I. MAOI and Meperidine Libby Zion 18 yo female Rx c phenelzine (Nardil) Meperidine given for shaking chills Outcome Death Libby
More informationImportance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie
More informationTitle of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)
Author of Lecture: Hilmer, Sarah (Dr.) Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009) COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material
More informationAFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June
AFPC Conference 2009 InterMed-Rx : Harmony and optimal therapy in the use of medication June 5 2009 Jacques Turgeon, B.Pharm., Ph.D. Full professor, Faculty of pharmacy Research Director, CHUM Université
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationDrug Interactions and ORT
Drug Interactions and ORT Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Methadone/buprenorphine pharmacology and toxicology will be covered
More informationDrug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health December 9, 2010 Drug Interactions:
More informationWhy do patients take herbs and nutritional supplements?
Why do patients take herbs and nutritional supplements? Dissatisfaction with conventional medicine > Relieve cancer-related symptoms > Treat adverse effects of anticancer drugs > Treat cancer > Promote
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful
More informationDrug Interactions: Let me count the ways
: Let me count the ways President: PRN Associates, Ltd. Continuing Education in Pharmacology Tucson, AZ Objectives At the conclusion of this continuing education lesson, the participant will be able to:
More informationCulture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationMODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL
MODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL ABSTRACT Quantitative prediction of the magnitude of drug-drug interactions (DDI) is critical to underwriting patient
More informationAnesthesiology, V 96, No 4, Apr
Anesthesiology 2002; 96:913 20 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationAlabama Medicaid DUR Board Meeting Minutes October 22, 2008
Alabama Medicaid DUR Board Meeting Minutes October 22, 2008 Members Present: Gurinder Doad, Paula Thompson, Rhonda Harden, Kevin Green, Bernie Olin, Clemice Hurst, Kelli Littlejohn, Kevin Royal, Tiffany
More informationMatthew D. Hall, NCI PCP 01/03/13
P-glycoprotein at the blood-brain barrier Matthew D. Hall Clinical Pharmacology Permeability-glycoprotein (P-gp): Efflux Transporter 1. Transports drugs out of cells in many locations e.g., placenta, brain
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationChapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More information2/25/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY OVERALL PRESCRIBING
Mean # Drugs/Resident 2/25/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY Darrell R. Abernethy, M.D., Ph.D. Associate Director for Drug Safety
More informationWithdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States
Bull. Natl. Inst. Health Sci., 123 Notes # Withdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States Journal of American Medical Association (JAMA) Statin HMG
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationDrug Interactions. Drug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health Drug Interactions: Definition The pharmacologic
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and
More informationTherapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University
Therapeutic drug monitoring Department of Clinical Pharmacology, Wrocław Medical University Therapeutic index concentration range characterized by a high efficacy of action and low risk of upper toxic
More information2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY
PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY Darrell R. Abernethy, M.D., Ph.D. Associate Director for Drug Safety Office of Clinical Pharmacology
More informationDifferent effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin K. T. Kivistö, T. Kantola & P. J. Neuvonen Department of Clinical Pharmacology, University of Helsinki and Helsinki
More informationA prospective study of the clarithromycin digoxin interaction in elderly patients
Journal of Antimicrobial Chemotherapy (2002) 50, 601 606 DOI: 10.1093/jac/dkf176 A prospective study of the clarithromycin digoxin interaction in elderly patients P. Zapater 1 *, S. Reus 2, A. Tello 2,
More informationLeslie Z. Benet, PhD. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University of California San Francisco
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Drug Interactions Leslie Z. Benet, PhD Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University
More informationChapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition
Chapter Questions Modern Pharmacology With Clinical Applications Sixth Edition Mechanism of Drug Action Questions 1. Receptors are macromolecules that a. Are designed to attract drugs b. Are resistant
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Oral solution 10 mg /ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY PROFILE Based on EU SmPC sections
More informationDEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA
METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationEvaluation of Drug-Drug Interactions FDA Perspective
Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More informationFluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2005.02467.x Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics Kerry E. Culm-Merdek, Lisa L.
More informationDrug Absorption and Bioavailability
Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 4, 2012 Office of Clinical Research Training and Medical Education National Institutes
More informationCore Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationAnnotation Guidelines
Annotation Guidelines Henk Harkema, Richard Boyce, Rob Guzman Version 1.9, 12/21/10 Introduction The purpose of this document is to provide instructions for the manual annotation of drug package inserts
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationWestern Veterinary Conference 2013
Western Veterinary Conference 2013 SA251 WHAT YOU DON T KNOW ABOUT P-GLYCOPROTEIN CAN HURT YOU (& YOUR PATIENTS!) Katrina L. Mealey DVM, PhD, Dipl. ACVIM, ACVCP Washington State University Pullman, WA,
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationEffects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
et al. British Journal of Clinical Pharmacology DOI:.46/j.365-5.3.3.x Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese Ichiro Fukazawa, Naoki Uchida, Eiji Uchida
More informationThe role of P-glycoprotein in limiting brain penetration of the peripherally acting
DMD This Fast article Forward. has not been Published copyedited on and formatted. April 23, The 2009 final as version doi:10.1124/dmd.109.027144 may differ from this version. DMD #27144 The role of P-glycoprotein
More informationFDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)
FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) Kellie S. Reynolds, Pharm.D. Deputy Director, Division of Clinical Pharmacology IV Office of Clinical Pharmacology (OCP) Office of
More informationClinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
INVITED ARTICLE REVIEWS OF ANTI-INFECTIVE AGENTS Louis D. Saravolatz, Section Editor Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents Roger
More informationEffects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
More informationSuitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity
Review Suitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity The Journal of Clinical Pharmacology XX(XX) 1 11 2013, The American College of
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationVariation in drug responses & Drug-Drug Interactions
Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources
More informationCOMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona
COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS Dan Malone, RPh, PhD Professor University of Arizona Disclosures I, Daniel Malone, have no financial relationships to disclose
More information3. P450 Drug Metabolism DDIs: Induction
35 3. P450 Drug Metabolism DDIs: Induction General Introductiona and Definition of a DDI: A drug-drug interaction (DDI) occurs when two drugs, each of which is safe and efficacious alone at their respective
More informationDrug Interactions Keeping it all Straight. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
Drug Interactions Keeping it all Straight Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationUCLA Nutrition Bytes. Title. Permalink. Journal ISSN. Author. Publication Date. Grapefruit Juice and Some Oral Drugs: A Bitter Combination
UCLA Nutrition Bytes Title Grapefruit Juice and Some Oral Drugs: A Bitter Combination Permalink https://escholarship.org/uc/item/7cn8p8k9 Journal Nutrition Bytes, 5(1) ISSN 1548-4327 Author Vu, Minh Chau
More informationRight drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationDevelopment of Drug Resistance and Strategies to Circumvent it: A Brief Look
Development of Drug Resistance and Strategies to Circumvent it: A Brief Look Jin-Ming Yang, MD, PhD The Cancer Institute of New Jersey Department of Pharmacology UMDNJ-Robert Wood Johnson Medical School
More informationINTERPLAY BETWEEN P-GLYCOPROTEIN-MEDIATED EFFLUX AND CYTOCHROME P4503A-MEDIATED METABOLISM IN THE INTESTINE
INTERPLAY BETWEEN P-GLYCOPROTEIN-MEDIATED EFFLUX AND CYTOCHROME P4503A-MEDIATED METABOLISM IN THE INTESTINE Beverly M. Knight A dissertation submitted to the faculty of the University of North Carolina
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationRHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY
RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY H Nägele (1)*, S.Behrens (1), S. Hashagen (1), M Azizi (2) 1) St. Adolfstift, Medical Clinic, Reinbek, Germany (Director:
More informationConcomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Concomitant administration of rifampicin and oxcarbazepine results in
More informationDrug metabolism and ageing
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2004.02096.x The Clinical Pharmacology of Ageing, edited by Dr A.A. Mangoni and colleagues, Department of Healthcare for the Elderly, Guy
More informationMany of the estimated 50 million Americans with high blood pressure receive medications
REVIEW ARTICLE Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension David A. Flockhart, MD, PhD; Jose E. Tanus-Santos, MD, PhD Many of the estimated 50 million Americans
More informationInfluence of allopurinol on drug metabolism in man
Br. J. Pharmac. (1973), 48, 693-698. Influence of allopurinol on drug metabolism in man M. D. RAWLINS* AND S. E. SMITH Departments of Medicine and Pharmacology, St. Thomas's Hospital Medical School, London
More informationIntroduction. British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:0./j.365-225.2005.02483.x Prediction of in vivo drug drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and
More informationM O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014
T H E R A P E U T I C D R U G M O N I T O R I N G Dr Tom Hartley UTAS HLS 2014 TOPICS 1) Why we do TDM 2) What drugs do we monitor 3) How our data assists Clinical Pharmacists & Doctors 4) Bioavailability
More information12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.
Drug Interactions Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc. Boston, MA, USA December 10, 2015 1 1 Overview Epidemiology and Categories of Drug
More informationSUMMARY INTRODUCTION. Accepted for publication 11 February 2003
Aliment Pharmacol Ther 2003; 17: 1015 1019. doi: 10.1046/j.0269-2813.2003.01550.x A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole,
More informationREPEATED ORAL RIFAMPICIN DECREASES THE JEJUNAL PERMEABILITY OF R/S-VERAPAMIL IN RATS
0090-9556/99/2708-0951 955$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 8 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. REPEATED ORAL RIFAMPICIN
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationBrainteaser NK-1 receptor antagonists
Brainteaser K-1 receptor antagonists 96 Strategies: Lower overall lipophilicity of compound - find areas of the molecule where logd can be lowered Identify and block sites of metabolism major site of metabolism
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationWELCOME BIENVENUE DRUG-DRUG INTERACTIONS
WELCOME BIENVENUE DRUG-DRUG INTERACTIONS DRUG-DRUG INTERACTIONS UPDATE ON THE STUDY DESIGN Didier Chassard, MD Medical and Scientific Associate Director Biotrial BIOTRIAL Drug Evaluation and Pharmacology
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationThe TC7 Cell Monolayer is a Valuable in vitro Intestinal Epithelial Model for Membrane Permeability Screening
The TC7 Cell Monolayer is a Valuable in vitro Intestinal Epithelial Model for Membrane Permeability Screening X.C. Wu, J.R. Williford, S. Gokhin, S. Lee, M.R. Davis, P. Sheffels, X. Wang, J. Migeon, and
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationVolume 9, Number 14 September 2015
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS 1 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT Ritonavir Tablets 100 mg * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationCytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules. George Zhang, Ph.D. April 18, 2012
Cytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules George Zhang, Ph.D. April 18, 2012 Presentation Overview Regulatory guidance Brief review on drug-drug (Disease) interactions
More informationPharmacokinetic Characteristics of Amiodarone in Long-Term Oral Therapy in Japanese Population
1934 Biol. Pharm. Bull. 28(10) 1934 1938 (2005) Vol. 28, No. 10 Pharmacokinetic Characteristics of Amiodarone in Long-Term Oral Therapy in Japanese Population Asami KASHIMA, a Miho FUNAHASHI, a Kyoko FUKUMOTO,
More informationPharmacogenetics and Pharmacokinetics
Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More information